Bedford, MA-based Hologic plans to take advantage of the excitement generated by the DMIST study by highlighting its work-in-progress breast tomosynthesis system with selenium-based full-field digital detector.
The company has conducted two years of diagnostic and screening trials for the system on the sensitivity and specificity of digital breast tomosynthesis as compared to 2D digital mammography, and will present these results at the RSNA show.
Hologic will also feature its multimodality workstation, SecurView, in its booth. SecurView displays and interprets screening or diagnostic digital mammograms and images generated by MRI, CT, PET, and ultrasound, and supports CAD programs. Hologic will also display its Selenia digital mammography system, MultiCare breast biopsy tables, and analog mammography system options.
Hologic made news earlier this year when it purchased Denver-based Fischer Imaging's mammography intellectual property assets. The deal effectively ended Fischer's participation in the mammography market and gave Hologic a wider customer base via Fischer's customer list and customer relationships. Hologic will not be showing any Fischer products at the RSNA meeting.
As for bone densitometry, the company will feature its work-in-progress Discovery DXA system, which incorporates a rotating C-arm that allows images acquired in different projections to be reconstructed to form 3D images of the femur.
By Kate Madden Yee
AuntMinnie.com contributing writer
November 7, 2005
Copyright © 2005 AuntMinnie.com
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
